Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: quietzsch d. Br J Cancer. 2000 Aug;83(4):458-62. doi: 10.1054/bjoc.2000.1295. Br J Cancer. 2000. PMID: 10945491 Free PMC article. Clinical Trial.
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C. Honecker F, et al. Among authors: quietzsch d. Anticancer Drugs. 2002 Jun;13(5):497-503. doi: 10.1097/00001813-200206000-00008. Anticancer Drugs. 2002. PMID: 12045461 Clinical Trial.
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: quietzsch d. Br J Cancer. 2003 Dec 1;89(11):2051-6. doi: 10.1038/sj.bjc.6601412. Br J Cancer. 2003. PMID: 14647137 Free PMC article. Clinical Trial.
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S, Haas M, Baechmann S, Altendorf-Hofmann A, Remold A, Quietzsch D, Clemens MR, Bentz M, Geissler M, Lambertz H, Kruger S, Kirchner T, Heinemann V, Boeck S. Ormanns S, et al. Among authors: quietzsch d. Br J Cancer. 2016 Dec 6;115(12):1520-1529. doi: 10.1038/bjc.2016.355. Epub 2016 Nov 1. Br J Cancer. 2016. PMID: 27802454 Free PMC article.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Heinemann V, et al. Among authors: quietzsch d. J Clin Oncol. 2006 Aug 20;24(24):3946-52. doi: 10.1200/JCO.2005.05.1490. J Clin Oncol. 2006. PMID: 16921047 Clinical Trial.
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V. Haas M, et al. Among authors: quietzsch d. Br J Cancer. 2017 May 23;116(11):1462-1469. doi: 10.1038/bjc.2017.115. Epub 2017 Apr 27. Br J Cancer. 2017. PMID: 28449008 Free PMC article.
35 results